Equities

Voyageur Pharmaceuticals Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
VM:CVE

Voyageur Pharmaceuticals Ltd

Actions
  • Price (CAD)0.14
  • Today's Change0.00 / 0.00%
  • Shares traded100.00
  • 1 Year change-15.15%
  • Beta0.0414
Data delayed at least 15 minutes, as of Feb 09 2026 17:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.

  • Revenue in CAD (TTM)11.04k
  • Net income in CAD-3.13m
  • Incorporated2008
  • Employees--
  • Location
    Voyageur Pharmaceuticals LtdDome Tower 800, 333 7 Ave. S.W.CALGARY T2P 2Z1CanadaCAN
  • Phone+1 (403) 923-5944
  • Fax+1 (403) 508-2670
  • Websitehttps://voyageurpharmaceuticals.ca/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pharmacielo Ltd2.83m-6.42m13.03m268.00------4.61-0.0356-0.03560.0156-0.07950.19941.714.10---45.28------3.13---227.15--0.0907-3.016.18--------------
Simply Solventless Concentrates Ltd30.71m4.17m18.31m192.009.070.57863.140.59630.01760.01760.26430.27650.7251.117.89159,949.409.84--13.15--28.99--13.57--0.7405-0.59810.3241--120.93---599.34------
Voyageur Pharmaceuticals Ltd11.04k-3.13m24.77m----17.31--2,244.00-0.0197-0.01970.000070.00810.00370.170.1428---103.95-78.90-250.45-135.25-25.63---28,307.25--0.5081--0.027-------21.99---1.10--
Data as of Feb 09 2026. Currency figures normalised to Voyageur Pharmaceuticals Ltd's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.